NEW YORK, NY / ACCESS Newswire / July 24, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Replimune Group, Inc. ("Replimune Group, Inc.") (NASDAQ:REPL) concerning ...
Hosted on MSN
Replimune Group (REPL) Nosedives 39% as FDA Approval for Melanoma Treatment ‘Uncertain’
We recently published 10 Stocks Losing Big Amid Market Boom. Replimune Group, Inc. (NASDAQ:REPL) is one of the worst performers on Thursday. Replimune extended losses to a second consecutive day on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback